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Abstract
Antiviral agents can be used to prevent HIV transmission before exposure as preexpo-sure
prophylaxis (PrEP), after exposure as postexposure prophylaxis, and as treatment of infected
people for secondary prevention. Considerable research has shed new light on antiviral agents for
PrEP and for prevention of secondary HIV transmission. While promising results have emerged
from several PrEP trials, the challenges of poor adherence among HIV-negative clients and
possible increase in sexual risk behaviors remain a concern. In addition, a broader pipeline of
antiviral agents for PrEP that focuses on genital tract pharmacology and safety and resistance
issues must be developed. Antiretroviral drugs have also been used to prevent HIV transmission
from HIV-infected patients to their HIV-discordant sexual partners. The HIV Prevention Trials
Network 052 trial demonstrated nearly complete prevention of HIV transmission by early
treatment of infection, but the generalizability of the results to other risk groups – including
intravenous drug users and MSM – has not been determined. Most importantly, the best strategy
for use of antiretroviral agents to reduce the spread of HIV at either the individual level or the
population level has not been developed, and remains the ultimate goal of this area of
investigation.
Keywords
antiretroviral agents; HIV prevention; preexposure prophylaxis; treatment as prevention
Introduction
Antiviral agents can be used to prevent HIV transmission in three ways: before exposure as
preexposure prophylaxis (PrEP), after exposure as postexposure prophylaxis (PEP), and as
treatment of infected people for secondary prevention [1–3]. PEP for HIV prevention has
been well established but is not well suited to clinical research investigation. However,
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recent research developments in PrEP and secondary prevention provide a unique
opportunity to highlight areas of advancement that have galvanized changes in HIV
treatment and prevention and to highlight topic areas that remain undecided or controversial.
Assessing the prevention benefits of antiretrovirals: pharmaceutical and
observational studies
With the development of antiviral agents in the early 1990s, a confluence of reasoning from
two disciplines emerged. Clinical pharmacological studies demonstrated that HIV drugs
penetrate the genital tract but with variable success [4–8]. Epidemiologic observational
studies suggested that antiretroviral therapy (ART) might play a role in reducing the sexual
transmission of HIV.
Intensive investigations of the pharmacology of antiretrovirals in genital secretions have
demonstrated that several drugs in different therapeutic classes of antiretrovirals reliably
concentrate in the male and female genital tract (Table 1). Drug penetration can be predicted
for semen by the degree of antiretroviral protein binding in blood. However, predictors of
drug penetration into the female genital tract remain unknown.
The relationship between the penetration of drugs into the genital tract, suppression of
genital tract replication with treatment, and the relevance of persistent HIV shedding to HIV
transmission remains only partially understood. First, it is clear that persistent intermittent
‘shedding’ of HIV in both male [9–14] and female [15–17] genital secretions can be
expected even when treatment has reduced the blood plasma viral load [18].
Several groups have reported detection of HIV in semen resistant to protease inhibitors
[19,20], reflecting poor penetration of this class of agents. Conversely, Ghosn et al. [21]
reported complete suppression of HIV in semen over 48 weeks with the lopinavir–ritonavir
combination, even though these agents were only detectable in blood plasma and not in
seminal plasma (<30 ng/ml). Inability to completely and consistently suppress replication of
HIV in the genital tract in men and women demonstrates that these compartments do not get
the full benefit of antiretrovirals. Indeed, quite recently, investigators have argued that the
persistent low copy HIV replication might be ascribed to poor penetration or metabolism of
ART in lymphoid tissues [22]. After a single dose of tenofovir, we have demonstrated
discrepant penetration into cervical, vaginal, and rectal tissues, with cervical and vaginal
tissue levels 10–100 times lower for tenofovir and tenofovir diphosphate than those
achieved in rectal tissue [23]. Sexually transmitted diseases (STDs) can stimulate shedding
of HIV in spite of antiviral therapy [24,25]. However, the results of observational reports
and the HIV Prevention Trials Network (HPTN) clinical trial 052 (see below) suggest that
HIV shedding (so readily observed in spite of treatment with antiviral agents) may not
actually contribute much to HIV transmission.
HIV transmission among HIV-serodiscordant couples has been the subject of several
observational studies [26,27]. A subset of these studies with information on index partner
ART status (Table 2) allows us to consider the effects of these drugs on transmission risk
[28–37]. Reduction of HIV transmission with treatment has been reported in all but one
report from China. In the study from China, 1927 infected people in stable HIV-discordant
couples were offered free ART [37]. Over 4918 person-years of follow-up time, similar
proportions of participants who were taking antiretrovirals and participants who were not
taking antiretrovirals infected their susceptible sexual partners (4.8 vs. 3.2%, P = 0.12).
However, there is no way to judge whether, or how, the infected persons were taking their
medications, and genetic tests were not performed to confirm linked transmissions within
the pairs.
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Attia et al. [26] undertook a meta-analysis that emphasized the limited data (five studies
total, with a combined 1098 person-years of follow-up) available from observational studies
for demonstrating transmission prevention related to ART. Nonetheless, these results, and
modeling of transmission probabilities with ART (reviewed in [38]), led to the rather
controversial 2007 ‘Swiss Statement’ [39]. In this declaration, the investigators concluded –
based on available data – that under particular circumstances, treated, HIV-infected persons
could engage in unprotected sex acts with minimal risk of transmission to an HIV-negative
partner. The Swiss Statement requirements included informed consent from the HIV-
negative partner, HIV-positive partner on ART suppressed to undetectable levels of blood
plasma HIV for at least 6 months, and lack of any other STDs. The Swiss people took these
recommendations seriously. In an analysis conducted among 7309 HIV-infected persons in
the Swiss HIV Cohort Study, after the Swiss Statement was issued, participants were 1.24–
2.04 (varied by risk group) times more likely to report unprotected sexual contacts [40].
Clinical trials in stable heterosexual couples and generalizability to other
contexts
To determine the magnitude and durability of a prevention effect from ART, a randomized
controlled trial was conducted by the HPTN [41]. In the HPTN 052 trial, 1763 sexually
active HIV-discordant couples (in a stable relationship over the past 3 months reporting
vaginal or anal intercourse at least three times during that period) were recruited from 13
sites in nine countries. At enrollment, the HIV-positive participant was required to be ART-
naive and have a CD4 cell count between 350 and 550 cells/μl; individuals with active
tuberculosis were excluded. Participants were randomized to start ART at study enrollment
(early therapy) or after two consecutive CD4 cell count measures less than or equal to 250
cells/ml and more than 200 cells/μl (delayed therapy). The history of the HPTN 052 trial has
been previously reported [42]. The HPTN 052 study is ongoing and scheduled for
completion in 2015. However, because of the overwhelming benefits of ART observed in
the first 1.7 years of average follow-up, the National Institutes of Health (NIH)
Multinational Data Safety Monitoring Board (DSMB) recommended on 28 April 2011 that
the sponsor (NIH) make the interim results available. The individuals in the early treatment
arm had greater than 96% protection from HIV acquisition from their HIV-infected partner
[41]. The single HIV transmission event in the treated group was ascribed to transmission
before HIV suppression was possible (Jabara, Ping, Swanstrom, personal communication).
Individuals in the early arm had reduced episodes of opportunistic infection, especially
extrapulmonary tuberculosis. Further analysis has demonstrated that patients receiving early
ART had delayed time to a primary HIV endpoint and significantly reduced secondary
clinical endpoints (Grinsztejn, et al., abstract submitted, IAS 2012). Following the DSMB
decision, all participants in the delayed treatment arm who had not already initiated
treatment (due to CD4 cell count <250 cells/μl) were offered antiretroviral drugs. HPTN 052
is continuing so as to determine the durability of the prevention benefit and to monitor
individuals in the delayed arm for adverse clinical events realized even after ART has been
initiated; an observational study has suggested that delayed initiation of ART even at higher
CD4 cell counts could lead to cardiovascular and other complications [43–45].
A key question from HPTN 052 is the generalizability to other contexts: heterosexual
couples with CD4 cell counts lower and higher than those studied in HPTN 052, high-risk
heterosexual individuals (e.g., sex workers and their clients), MSM, and intravenous drug
users (IDUs). There are no data to address this issue directly. The PEPFAR Scientific
Advisory Board concluded that for heterosexual transmission, there is no reason to believe
that ART will not suppress HIV transmission regardless of pretreatment viral burden or
stage of disease [46]. For MSM, a WHO Expert Committee concluded that there is no
reason to presume that treated, HIV-infected MSM will not be rendered less contagious [47].
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However, the biology of HIV transmission is sufficiently different in IDUs and MSM as
compared with heterosexual transmission, warranting further consideration and study (K.E.
Muessig, et al., under review).
For example, the number of HIV variants acquired and the efficiency of transmission are
higher in MSM and IDU than in heterosexual transmission [48]. Additionally, whether ART
reduces infectivity through anal sex by the same order of magnitude as for vaginal sex
remains uncertain (K.E. Muessig, et al., under review). Although such an effect is widely
assumed, this is a key missing piece of evidence. Although an individual-level clinical trial
among MSM may be unethical in light of the results of HPTN 052, at least two
observational studies are underway to assess the effects of ART on HIV transmission among
MSM. The Partners of People on ART: A New Evaluation of the Risks (PARTNER) Study
[49] and the ‘Opposites Attract’ study [50] will recruit serodiscordant male–male couples in
Europe and Australia/Thailand, respectively. In these studies, serodiscordant couples who
are engaging in anal intercourse, and in whom the HIV-infected partner is on ART, will be
followed longitudinally to estimate the rate of HIV transmission.
Antiretroviral treatment and population-level benefits
The individual benefits of ART may translate to a population-level effect in some parts of
the world; however, the data used to support this conclusion have been controversial in large
part because of the limitations of the methods employed (Smith, et al., under review). Eight
published ecological studies have examined trends in the HIV epidemic – in some cases
using measures of HIV incidence – and concomitant availability of antiretrovirals (Table 3)
[51–58]. These studies are interesting and provocative, but they are inevitably subject to
considerable confounding and bias. The measurement of antiretroviral use is also
problematic, as HIV transmission can only be prevented with reliable and durable
suppression of HIV.
Ecological studies have had mixed results. In San Francisco, investigators argue that new
diagnoses of HIV have fallen as a result of broader availability of ART and demonstrable
reduction in viremia in some members of the ‘community’, broadly defined as people with
recognized HIV who are receiving treatment [52]. In British Columbia, antiretrovirals have
been related to reductions in new diagnoses of HIV among IDUs [53], a population that has
received many other successful interventions [59,60] and in whom adherence to
antiretrovirals may be poor [61]. HIV incidence among other groups such as MSM in the
USA, Australia, France and Amsterdam may be rising, in spite of the wide availability of
antiretroviral drugs [62–66]. In Canada, the portion of MSM making up the estimated
number of incident infections increased between 2005 and 2008 [67]. Conversely, HIV
incidence worldwide has been falling dramatically; between 2001 and 2009, HIV incidence
decreased by more than 25% in 33 countries, 22 of which were in sub-Saharan Africa [68].
These declines are most readily ascribed to a complex set of interventions including
antiretroviral drugs. So, although it is certainly possible that ART is reducing the incidence
of HIV in communities with broad access to ART, the methods used in ecological studies,
along with a large number of unaddressed issues and incongruent results, preclude a
definitive answer to this hypothesis.
Most recently, investigators in South Africa reported results from a study in KwaZulu-Natal
in which they compared the densityof ART coverage in different communities with HIV
sero-conversion in a longitudinal cohort of 16 667 people. They adjusted their analysis to
consider sexual behavior, socio-demographic variables associated with HIV acquisition, and
HIV prevalence in the surrounding community (range <10 to >40%). In the adjusted
analysis, each percentage point increase in ART coverage of all HIV-positive persons in the
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surrounding community resulted in a 1.7% (P < 0.001) reduction in risk of HIV acquisition
for HIV-negative persons living in that community [69]. These results present the most
compelling population-level evidence to date that treatment with ART can reduce incidence
of HIV.
Community randomized trials
Given the need to understand the proper balance between antiretrovirals and other modes of
HIV prevention, as well as the magnitude of benefit of combination prevention, population-
level clinical trials are planned. At least 50 studies are ongoing or planned [70], some of
which are quite ambitious. HPTN 065 is a study designed to determine whether people with
HIV in New York City and Washington, District of Columbia, can be detected and
efficiently linked to care [71]. Three studies are being supported by a variety of agencies
including the Office of the Global AIDS Coordinator (PEPFAR), USAID, the Bill and
Melinda Gates Foundation, the US Centers for Disease Control (CDC) and the US NIH, and
one study by the French National Agency for Research on AIDS and viral hepatitis (ANRS).
In a study in Botswana, the investigators intend to find and treat people with the highest
viral loads, as they may be most contagious [72]. All of these studies are likely to use
molecular phylogeny to better understand the spread of HIV, and new cases introduced from
outside the target communities.
Treatment as prevention, though exciting, cannot be guaranteed success at the population
level. Can enough people be detected, linked to care, and properly treated to make a
difference [73–75]? Also, current HIV detection strategies cannot find people with acute and
early HIV disease [74,75], who may or may not contribute greatly to the spread of HIV [76–
79]. The biology and epidemiology of acute HIV infection have been extensively reviewed;
the relative importance of acute HIV infection to the spread of HIV is the subject of current
debate [80].
Preexposure prophylaxis
PrEP is used to prevent many infectious diseases (e.g., endocarditis, malaria). However,
usage of PrEP is subject to universal questions: does the agent work (biological plausibility);
can the agent be given at the right time to work (pharmacokinetics and dynamics); will at-
risk individuals use the agent properly and reliably; will cost and toxicity outweigh the
benefit(s) of the intervention; and is usage sufficiently limited? In essence, the right drugs
must be used at the right time for the right duration.
Attempts to develop PrEP regimens for HIV have been challenging, and the results
confusing. We have summarized the work from seven trials (Table 4) [41,81–86]. To date, a
limited number of agents have been used, selected primarily because they are well tolerated
and because they provided protection in a macaque model using either rectal or vaginal
exposure to SIV [87,88]. However (as discussed below), the relative safety of daily oral
tenofovir for HIV-negative people has been questioned [89].
Two trials have used 1% tenofovir gel intravaginally with different results. Although the
populations were similar, the dosage schedules were different. In the CAPRISA 004 study
[81] heterosexual women at high risk of infection, ages 18–40 years, used the gel in a
coitally dependent manner: one dose of gel up to 12 h before sex and one dose of gel up to
12 h after sex, with no more than two doses in 24 h. In one arm of the VOICE trial [86],
women ages 18–45 used a dose of gel daily, regardless of sexual activity. The CAPRISA
004 study demonstrated 39% protection against HIV acquisition by tenofovir gel, whereas
the tenofovir gel arm of the VOICE trial was stopped for futility. The reasons for the failure
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of tenofovir gel in VOICE trial after the success of CAPRISA 004 have not yet been
determined.
Five studies of oral PrEP have been undertaken (Table 4) [82–86]. iPrEx is the only study
devoted to MSM. In this trial [82], 2499 MSM in South America and the USA were
provided a daily fixed-dose combination pill of tenofovir with emtricitabine. The
investigators reported a 44% reduction in HIV acquisition compared with placebo controls.
Data were also analyzed to consider self-reported pill usage. Incidence was reduced by 73%
if self-reported adherence was high (>90% of doses taken), 50% if adherence was
intermediate (>50% of doses), and 32% if adherence was low (<50% of doses). Among
those who reported good adherence (taking study drug 50% of days), 46% of men who
remained HIV-negative and 92% of men who seroconverted had no drug detected in
selected blood and cell samples (Grant et al., 2010, Supplemental Table 8). The iPrEx
investigators also used a case–control design to measure the association between detectable
antiretrovirals in blood plasma and peripheral blood mononuclear cells and incident HIV
infection. The majority of incident infections in the study drug arm had pharmacokinetic
data available (34/36), and only 9% of these individuals had detectable study drug levels in
selected plasma and cell specimens as compared with 51% of those who did not become
infected. On the basis of this result, the authors argue that PrEP resulted in a relative risk
reduction of 92% [95% confidence interval (CI) 40–99%] comparing patients with
detectable study drug levels to those without detectable drug levels. Despite these promising
findings, both self-report and pharmacologic markers raise concerns for accurately and
reliably measuring drug adherence, an issue we discuss below.
Three studies of oral PrEP have involved women. The TDF2 study [83] enrolled 540 women
and 660 men randomized to receive a daily fixed dose combination pill of tenofovir–
emtricitabine or placebo. Study participants were predominantly unmarried adults ages 21–
29 years living in Botswana. In this study, tenofovir–emtricitabine offered 64% protection
against HIV infection. However, the study numbers were too small to draw definitive
conclusions about protection in men and women separately, and 30% of those enrolled did
not complete the study. In the FEM-PrEP study [85,90], 2120 heterosexual women aged 18–
45 years living in high-prevalence areas in Kenya, South Africa, and Tanzania were
randomized to receive either daily tenofovir–emtricitabine (FTC/TDF) or placebo. This
study was discontinued for futility in April 2011. The investigators recently reported an HIV
incidence rate of 4.7/100 person-years among the FTC/TDF group and 5.0/100 person-years
in the placebo group for a hazard ratio for infection of 0.94 (95% CI 0.59–1.52, P = 0.81)
[90]. Adherence may have been a critical contributing factor as less than 50% of infected
cases and uninfected matched controls had detectable study drug in their blood plasma.
Finally, the VOICE (MTN-003) study [86] enrolled heterosexual women aged 18–45 years
in high-prevalence areas of Uganda, South Africa, and Zimbabwe. Women were randomized
to daily oral tenofovir or daily oral tenofovir–emtricitabine. In September 2011, the daily
oral tenofovir arm was stopped for futility, whereas the daily oral tenofovir–emtricitabine
arm continues.
The largest trial, Partners in Prevention, focused on 4758 discordant heterosexual couples in
Kenya and Uganda (38% negative women and 62% negative men) who reported intensive
condom use and received counseling, in addition to the seronegative partner receiving daily
tenofovir or daily tenofovir–emtricitabine. At the 2011 International AIDS Society meeting,
the investigators reported that daily tenofovir conferred 62% protection against HIV
acquisition and daily tenofovir–emtricitabine conferred 73% protection against HIV
acquisition [83]. At the 2012 Conference for Retroviruses and Opportunistic Infections, the
authors updated their results reporting 67% protection from daily tenofovir and 75%
protection from the combined regimen [91]. Only two individuals who were infected at
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randomization and one individual infected after randomization developed resistance (K65R
or M184V mutation).
These trials differ in many ways. However, clearly, poor adherence would limit success as
reported for FEM-PrEP and iPrEx. It is also possible that the drugs employed are not
perfectly suited to PrEP, especially in women. Substantial differences in antiretroviral drug
concentrations in mucosal tissues have been reported [23,92], which may help explain these
discordant study findings [93]. As noted above, after the first dose of oral FTC/TDF, rectal
tissue concentrations are far greater than cervical or vaginal tissue concentrations [23]. This
could explain why tenofovir–emtricitabine conferred protective efficacy in iPrEx [82],
despite only modest adherence. In the VOICE 003 trial [86], the lack of protection with oral
TDF could reflect low tissue concentrations of the drug in the cervix and vagina.
Furthermore, differences between study populations in risk behaviors and underlying rate of
infection deserve consideration.
Two new studies (HPTN 067 and HPTN 069) sponsored by the HIV Prevention Trials
Network (HPTN), one study sponsored by ANRS (IPERGAY), and an extension of the
iPrEx study (iPrEx OLE) are addressing some of the limitations of the previous PrEP
studies. Due to the adherence issues with daily PrEP dosing, the behavioral study HPTN 067
(the ADAPT study: Alternative Dosing to Augment PrEP Pill-Taking) is designed to test the
hypothesis that recommending intermittent usage of oral tenofovir–emtricitabine, compared
with recommending daily usage, will be associated with equivalent coverage of sex events
before and after exposure dosing, lower number of pills needed for coverage, and decreased
severity and frequency of self-reported side effects [94]. HPTN 067 is enrolling 180 MSM
and 180 heterosexual women and aims to identify dosing regimens that foster healthy sexual
practices and pill-taking behavior in people at high risk of infection. The study includes a 6-
week lead-in period, which includes directly observed therapy at enrollment and weeks 1
through 4, followed by 1 week without dosing to determine individual steady-state
pharmacokinetics. Participants are then randomly assigned to one of three dosage groups in
a 1 : 1 : 1 ratio: daily dosing, time-driven dosing, and event-driven dosing to be completed
over 24 weeks.
iPrEx OLE (open-label extension) is a continuation of the iPrEx study that is enrolling
participants in 11 sites in Peru, Ecuador, Brazil, the USA, South Africa, and Thailand [95].
It is hoped that knowing with certainty that one is on the study drug (and not placebo) will
lead to higher medication adherence. The 72-week study will also assess the long-term
efficacy and safety of PrEP, changes in sexual behavior, drug resistance, changes in bone
mineral density and fat distribution, and the impact on hepatitis infection.
The IPERGAY study sponsored by ANRS is a randomized controlled trial among HIV-
negative MSM testing the prevention efficacy of Truvada (tenofovir–emtricitabine; Gilead
Sciences Inc., Foster City, California, USA) in combination with regular HIV/STD testing,
immunization against hepatitis A and B, postexposure treatment as needed, and condom
distribution [96]. Enrollment is currently ongoing in France and will also be extended to
Canada.
Due to the possible limitations related to efficacy and toxicity (see below) of tenofovir–
emtricitabine, HPTN 069 (NEXT-PrEP: Novel Exploration of Therapeutics for PREP) is
assessing the safety and tolerability of maraviroc-containing PrEP regimens [97]. HPTN 069
is enrolling 400 MSM and 200 heterosexual women and will compare 48-week safety and
tolerability of daily maraviroc, maraviroc–emtricitabine, maraviroc–tenofovir, or tenofovir–
emtricitabine. Secondary objectives will include evaluation of electronically monitored
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adherence, pharmacokinetics in systemic and genital tract compartments, and efficacy of ex-
vivo HIV challenge in tissue biopsy explants.
Alternative drugs and delivery systems more appropriate to PrEP are also being pursued.
Vaginal rings for women containing antiretrovirals would be similar in concept to vaginal
rings currently used for contraception and hormone replacement therapy [98]. These rings
could maintain long-term, sustained antiretroviral release for local efficacy. Due to the long-
term drug release, rings can be used in a coitally independent manner and inserted monthly,
which could have an adherence benefit over gels or pills.
Dapivirine [TMC120; Janssen R&D Ireland (previously Tibotec)] has been formulated into
a ring and is currently undergoing phase III studies [99]. Two phase I studies evaluating
dapivirine 25 or 200 mg delivered from a vaginal ring over 7 days in 25 healthy women
found the ring to be well tolerated, with adverse effects similar to placebo. Mucosal fluid
sampled at up to 7 days after insertion in all women from the introitus, cervix, and ring area
had mean drug concentrations 1000 times the 50% effective concentration (EC50) against
wild-type HIV-1 [100,101]. A combination dapivirine and maraviroc ring is currently
undergoing a phase 1 safety and pharmaco-kinetic study.
An alternate formulation for better adherence is a long-acting injectable product that could
be administered every 30–90 days. A rilpivirine (RPV) (TMC278 LA) nanosuspension is in
early phase of development for this purpose [102,103]. In an exploratory study among 32
HIV-negative participants, a single intramuscular injection with either 300, 600, or 1200 mg
of RPV showed varying, prolonged plasma, genital tract, and male rectum concentrations
over 84 days [103]. Optimal dosage, differences in drug concentrations in various biological
compartments, and long-term safety of multiple doses all require further study.
Although a potentially strong addition to the biomedical technologies available for HIV
prevention, PrEP has given rise to a number of concerns [104]. First, HIV resistance is an
important consideration while using oral antiviral agents. Among the 10 individuals enrolled
in iPrEx with unrecognized HIV infection at baseline (and therefore subsequent unwitting
exposure to ART directed at PrEP rather than treatment), three developed FTC-resistant
mutations; this resistant mutation would be expected from the double-drug therapy
employed [105]. However, among 36 men who became HIV infected during the trial in the
FTC-TDF group, no ART resistance was observed. These results have sometimes been
interpreted to indicate that PrEP does not threaten the utility of the ART agents used [106].
However, given the low adherence rates recorded in iPrEx, these results could also suggest
that the study individuals used no ART product during the time after HIV was acquired and
diagnosed. Detection of ART resistance markers represents a surrogate for failed PrEP
usage, and ART resistance might compromise future management of people using PrEP who
acquire HIV [105].
Second, the long-term biological impacts of FTC-TDF taken for PrEP purposes (as
compared with HIV treatment purposes) will require additional study. Specifically, tenofovir
has been linked with renal injury [89,107] and loss of bone mineral density (BMD) [108]
when used for HIV treatment. Individuals with preexisting renal conditions have been
excluded from PrEP studies [109,110]. In the iPrEx study, a nonsignificant trend toward
elevated creatinine levels was found among the intervention arm [81], and a substudy
showed a small but significant (up to 1%) loss in BMD [111].
An additional concern is that the use of ART as PrEP could affect sexual behavior [112]. In
the iPrEx study, the investigators reported no increase in sexual risk behaviors. However, an
individual's behavior within an unproven medical trial as compared with behavior of an
individual under the belief of effective PrEP in a real-world setting must also be considered.
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‘Risk compensation’, wherein individuals alter their behaviors in response to perceptions of
risk, has been documented in relation to the availability of antiretroviral drugs and other
biomedical HIV-prevention approaches [113–115]. Furthermore, even within a controlled
trial setting such as the iPrEx study, self-reported adherence to ART was less than perfect,
and other STDs were detected in both groups, challenging the veracity of the behavioral data
collected. Finally, PrEP has generated discussions about resource distribution and how to
balance the current HIV treatment coverage gap with expansion of preexposure prevention
measures [116].
Taking antiretroviral treatment to scale: modeling, observation, and
empirical data
Although investigators have been evaluating the potential utility of antiviral agents for
prevention, a virtual parallel universe of researchers have been making the case that the
benefits of ART are both inevitable, and already visible. This work has been conducted
through evaluation of observational and ecologic data and mathematical modeling.
Mathematical modelers take the best available data and make assumptions about biology
and behaviors to provide predictions of the future that are often provocative. A large number
of models have focused on the usage of ART by HIV-infected persons to reduce the spread
of HIV (Table 5) [117–125], as described in numerous review articles [2,126–128]. The
results of several such modeling studies have suggested that expanded ART use could result
in substantial reductions in HIV incidence under certain, optimistic conditions [120,129].
However, modeling studies have also shown that the population-level transmission
prevention benefits of ART could be severely compromised by such factors as increased risk
behavior [130–132], ongoing transmission during acute and early HIV infection [133],
antiretroviral drug resistance [124], concentration of risk in population subgroups [122], and
sub-optimal ART coverage, effectiveness, or adherence [125,134] (Table 5). Considerable
uncertainty surrounds the fundamental assumptions and parameter values used in these
models; more empirical data about risk behavior patterns, STD co-transmission, ART uptake
and adherence, and effects of ART on infectivity (especially for anal contact and parenteral
transmission) will facilitate more reliable model projections.
One area of special interest is the potential balance between PrEP and treatment, as well as
the targeted use of antiretroviral-based prevention strategies within discordant couples.
Using available data to look at management of HIV-discordant couples, Hallett et al. [135]
reported that use of PrEP by the uninfected partner could be at least as cost-effective as
earlier ART initiation by the infected partner, provided that the annual cost of PrEP is less
than 40% the cost of ART and the effectiveness of PrEP exceeds 70%. At the population
level, Pretorius et al. [136] used a mathematical model to examine the impact and cost-
effectiveness of PrEP relative to ART in South Africa. These investigators concluded that
PrEP use would be most cost-effective if utilized before ART reaches 65% of HIV-positive
persons; as ART coverage increased beyond this level, the cost-effectiveness of PrEP was
predicted to decrease rapidly. El-Sadr et al. [137] evaluated treatment of HIV-infected
partners within serodiscordant couples as a strategy for reducing HIV incidence at the
population level and found that the predicted effectiveness in a given setting depended on
HIV prevalence and the degree of HIV discordancy. In general, these results do not support
a focus on HIV-discordant couples for public health purposes. As with the modeling studies
of treatment as prevention described above, these studies indicate that PrEP effectiveness
will depend on many factors and that the choice of intervention must take into account the
epidemiological context in a given setting.
Cohen et al. Page 9













Combination prevention: the way forward
Implementation of ART as prevention faces substantial challenges, including logistic
limitations [73,75], potential changes in risk-taking behaviors, and cost. Indeed, ART usage
will need to be part of a combination strategy [138]. In a remarkable 2011 speech at the
NIH, Secretary of State Hillary Clinton expressed hope for an ‘AIDS Free Generation’
[139]. On World AIDS Day 2011, President Barack Obama pledged an additional US$ 35
million for state AIDS drug assistance programs based on the HPTN 052 findings [140].
PEPFAR and the WHO have recommended the use of ART to prevent HIV transmission
among heterosexual partners [46,141], and UNAIDS is looking into similar guidelines [68].
But attention to broader use of ART cannot ignore other parts of a prevention package [138].
Secretary Clinton concluded that broader prevention of mother-to-child transmission, more
circumcision, and optimal and broader use of ART will point us in the right direction [139].
Additionally, combination prevention strategies [142] will need the continued efforts of
behavioral interventions to increase condom use, reduce high-risk behaviors, and address
suboptimal antiretroviral adherence and risk compensation. The community-based clinical
trials described in this article, though focused on ART, all embrace a similar combination
prevention strategy. And all of these trials and advances must also recognize the important
discoveries in the field of HIV vaccine [143,144]. It seems reasonable to expect that – after
30 years of work – the tools now available in the HIV prevention toolbox and those that will
become available from ongoing research can be expected to control the spread of HIV.
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Table 2
Studies assessing effects of antiretroviral treatment on HIV transmission.
Author Study location No. of couples Study population Conclusions
Retrospective cohorts
    Musicco et al. [34] Italy 436 HIV + clinic and HIV
surveillance center clients and
their seronegative partners
ART in HIV-infected men reduces, but
does not eliminate, heterosexual
transmission of infection
    Castilla et al. [28] Spain 393 HIV clinic patients and their
seronegative partners
Combined ART applied according to
current guidelines has a great potential
for preventing HIV transmission to
sexual partners
Prospective cohorts
    Bunnell et al. [31] Uganda 926 ART-naive HIV-positive adults
enrolled in home-based ART
program reporting on their
partners (stable/nonstable, HIV-
positive/negative)
ART, prevention counseling, and
partner VCT associated with reduced
estimated risk of HIV transmission
during first 6 months of therapy
    Del Romero et al. [29] Spain 424 Couples recruited through HIV-
positive patients at an HIV/STI
clinic
Heterosexual infectivity of HIV in
individuals taking effective
antiretroviral treatment is low




3381 HIV-positive and HSV-positive
individuals and their HIV-
negative partners from the
partners in prevention HSV/
HIV Transmission Study
Provision of ART to HIV-infected
patients could be an effective strategy
to achieve population-level reductions
in HIV transmission
    Hernando et al. [32] Spain 339 HIV-positive patients and their
partners attending a HIV/STI
clinic
Couples-based safe sex counseling and
ART can reduce but not eliminate
sexual HIV transmission
    Melo et al. [33] Brazil 93 HIV clinic patients and their
seronegative partners
Transmitters showed significantly
higher median viral loads, suggesting
that heterosexual transmission of HIV
is more a function of viral load than
sex of index case. Antiretroviral use
may play a role in the prevention of
HIV heterosexual transmission
    Reynolds et al. [35] Uganda 250 Serodiscordant couples offered
free ART if eligible
HIV transmission may be reduced
among HIV-discordant couples after
initiation of ART due to reductions in
viral load and increased consistent
condom use
    Sullivan et al. [36] Rwanda, Zambia 2993 Serodiscordant couples initiated
on ART if eligible
ART was associated with a 94%
reduction in transmission; ART
initiation is a critical component of a
package of biomedical and behavioral
prevention services
    Wang et al. [37] China 1927 Former plasma donors and their
seronegative spouses
Transmission events occurred with
equal frequency in couples regardless
of whether the partner was provided
ART
ART, antiretroviral therapy; HSV, herpes simplex virus; STI, sexually transmitted infections; VCT, voluntary counseling and testing.
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Table 3
Ecological studies.
Author Analysis method Statistical analysis results Conclusions
Castel et al.
[51]
Negative binomial regression of new
diagnoses on mean CVL
Lack of association reported (P = 0.11) No association was found
between trends in the mean
CVL and newly diagnosed
HIV/AIDS cases
Das et al. [52] Poisson regression of new diagnoses on
changes in total and mean CVL; meta-
regression of estimated incidence on
changes in total and mean CVL
Statistically significant trend with new
diagnoses noted (P = 0.003); lack of
association using estimated incidence (P >
0.30)
Reductions in CVL were
associated with decrease in
new HIV diagnoses but not




Modified back-calculation to estimate
reduction in transmission rate (new cases
per prevalent case-year) between pre-
ART and post-ART eras
Pre-ART transmission rate estimated as 0.391
new infections per prevalent case; post-ART
transmission rate estimated as 0.184 new
infections per prevalent case
Provision of free ART was
associated with a 53%




Inferences drawn from observation of
concurrent changes in HIV incidence
rates, reported sexual behavior, STI
diagnoses, and ART use among
population in clinical care






Inferences drawn from predicted changes
in prevalence of undetectable VL among
population in clinical care and external
reports of HIV incidence
– Declines in predicted
detectable viral load 1997–
2009 coincide with reports of
rising new diagnoses and




Poisson regression of estimated new
diagnoses on changes in median CVL
and numbers receiving ART
Effect of 100 new patients receiving ART on
estimated new diagnoses predicted as –0.97
(95% CI 0.96–0.98); effect of 1 log decrease
median CVL on the estimated new diagnoses
predicted as –0.86 (0.75–0.98)
Increased ART coverage and
reduced CVL are associated




Inferences drawn from trends in annual
HIV incidence based on antibody testing
and time period (pre-ART versus post-
ART period) as indicator of ART use
– Wider availability of ART
appears to have slowed




Unadjusted and adjusted Cox
proportional hazards regression of time to
seroconversion on median CVL in the
preceding 6 months
Unadjusted hazard ratio for effect of median
CVL on time to seroconversion estimated as
3.57 (2.03–6.27) per log10 CVL increase;
adjusted hazard ratio for effect of median
CVL on time to seroconversion estimated as
3.32 (1.82–6.08) per log10 CVL increase
Median CVL predicts HIV
incidence independent of HIV
risk behaviors
ART, antiretroviral therapy; CI, confidence interval; CVL, community viral load; IDUs, intravenous drug users; STI, sexually transmitted
infection.
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Table 5
Selected modeling studies examining the impact of treatment as prevention on the HIV epidemic.
Source Model setting Model risk group(s) Main predictions
Blower et al. [117] San Francisco MSM Increased ART use could substantially reduce epidemic, but if risk
behavior increases as a direct result of increased ART use, net benefit
could be ~0
Gray et al. [118] Uganda Heterosexuals ART alone cannot control mature HIV epidemics; ART in
combination with a low-efficacy vaccine and in the absence of
behavioral disinhibition could control the epidemic
Baggaley et al.
[119]
Southern Africa Heterosexuals Increased treatment is unlikely to control the epidemic, regardless of
extent of ART roll-out; counseling to reduce risk behaviors is
essential




The Netherlands MSM Decreasing risk behavior will have the greatest impact on the HIV
epidemic, but earlier diagnosis and treatment can also prevent
substantial numbers of infections
Dodd et al. [122] Theoretical Heterosexuals Test-and-treat interventions can substantially reduce HIV
transmission in some contexts, but inadequate intervention coverage
and uneven distribution of risk behaviors could dramatically
compromise effectiveness
Long et al. [123] USA MSM, IDUs, heterosexuals Substantial reductions in risk behavior will be required to markedly
affect the epidemic, even with substantial expansion of HIV screening
and treatment
Smith et al. [124] San Francisco MSM Transmission of antiretroviral-resistant strains could substantially
compromise HIV treatment programs
Walensky et al.
[125]
Washington, DC Not specified A test-and-treat intervention with annual testing and realistic rates of
intervention uptake is unlikely to halt the HIV epidemic
ART, antiretroviral therapy; IDUs, intravenous drug users.
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